Startups · 27. 10. 2026.1 min read
Orphan Therapeutics Accelerator In-Licenses Investigational Gene Therapy Program for Ornithine Transcarbamylase Deficiency from UCL Ventures and Children's Medical Research Institute
Локални аутоматски превод · Изворни језик извора
Сажетак
OTXL-101, a promising therapy in development for a severe, rare pediatric metabolic condition, becomes the first pipeline program to be in-licensed by Orphan Therapeutics Accelerator (OTXL) CAMBRIDGE, Mass., Oct. 27,…
Изворни језик извора: PR Newswire UK — News ReleasesПрочитајте оригинал →